Devika Das, MD, MSHQS, FASCO

Division Director of Hematology/Oncology, Associate Director - Clinical Affairs at the cancer institute @ummc_cancer @ummcMedicine
🫁 Oncology, QI/Safety Expert

[Devika Das, MD, MSHQS, FASCO @DevikaDasMD]

@GlopesMd @WSJopinion @WSJ Congratulations! Wonderful write up 👏👏

[ASCO @ASCO]

Thank you @SenHydeSmith for your Senate floor speech on the harms of prior auth. We appreciate your support of the ASCO-endorsed Seniors’ Act and Safe Step Act to reduce utilization management burdens to get care to patients faster. #FixPriorAuth #ASCOAdvocacy

[Ashley Love Sumrall, MD, FACP, FASCO @AshleySumrallMD]

🚨🚨🚨Thank you, @RepNancyMace & @Rep_Whitesides for bringing the cosponsors to 290 for @MikeKellyPA’s Seniors’ Act!
👉🏻 Let’s get it to the floor & voted on! #HR3514
- STOP faxes!
- Increase transparency! @asco #asco26 #advocacy #AMAmtg

[Oncology Brothers @OncBrothers]

Data from 4 studies that we touched on during our Lung Cancer Conference Highlights from #ASCO26 w/ @ipreeshagul

✅ #LIBRETTO432
✅ #CROWN
✅ #CHRYSALIS2
✅ #HARMONi6

#lcsm #OncTwitter @OncUpdates

[Raffaele Colombo @raffcolo]

ABBV-706 (SEZ6 Topo1i ADC) in R/R SCLC and other solid tumors. Phase 1 data published in @NatureMedicine

Responses were seen across all SEZ6 expression levels.

No correlation of SEZ6 expression was observed with PFS and OS based on median H-score.

https://t.co/yUEonJygIA

[UMMC Cancer Center and Research Institute @UMMC_Cancer]

What drives the mission of the UMMC Cancer Center and Research Institute? Dr. Rod Rocconi sat down with Dr. LouAnn Woodward to talk about it in UMMC’s latest Coffee Talk video. Give it a watch. 💙
https://t.co/Ufkc65KGlU

[Rod Rocconi @rodrocconi]

Research that informs us to achieve #AHealthierMississippi #ONEmississippi #cancercareintheSIP

[Devika Das, MD, MSHQS, FASCO @DevikaDasMD]

@AshleySumrallMD @ASCO @fumikochino @steveleeyc @cancerassassin1 @atanmdlci @BrainTumorDoc @OdiaYazmin @RoyStrowdMD @msheenmd @DrMMurphy Always a joy to see you make it to your meeting montage 💖 #ASCO26

[Samuel Hume @DrSamuelBHume]

4. What's next for Daraxonrasib? More trials!

1st line in metastatic pancreatic cancer, and after surgery in resectable disease; in lung cancer; and in other solid cancers, like colorectal

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

☢️ Concurrent thoracic radiotherapy + chemotherapy + durvalumab phase III trial in stage IV SCLC stopped early due to excess of deaths in the radiotherapy arm.
Not improvement in ORR, PFS, or OS but added toxicity to standard CASPIAN.
A definitively NOT TO DO. #ASCO26 #LCSM

[Devika Das, MD, MSHQS, FASCO @DevikaDasMD]

Great discussion by @drshieldsmd
More clinical trial enrollment and biomarker identification for patient selection in the #sclcsm population will be key! #lcsm #ASCO2026

[Devika Das, MD, MSHQS, FASCO @DevikaDasMD]

Catching this session from the airport but SEZ6 targeting seems to be a promising avenue in small cell lung cancer. We have a serious burden of this deadly cancer in our population and are looking forward to bringing access to few of the future trials with this molecule soon! #lcsm #sclcsm
@asco #ASCO26
Congratulations to @LaurenByersMD and team on the study!

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

💊 Another win for lorlatinib during this meeting, now in the neoadjuvant setting.
LORIN trial: pCR 47%/MPR 81%
Strong suggestion to add a Trop2 ADC to remove DTPC
#ASCO26 #LCSM

[gilberto lopes @GlopesMd]

Here is an algorithm for RET fusion–positive NSCLC: evolving adjuvant and metastatic targeted therapies on @OpenMedicineHQ. Interactive, evidence-linked, open for discussion. Feedback welcome. #LivingAlgorithms
https://t.co/ETNDBbf5Uc

#ASCO26 @OncoAlert @OncBrothers @StephenVLiu @Jani_Chinmay @asco @myESMO @glopesmd @SylvesterCancer @latinamd @iaslc @COlazagasti @openevidence @openmedicinehq @narjustflorezmd @lungoncdoc @drshieldsmd @jackwestmd @n8pennell @mtmdphd @drarturoai @larvol @onclive @rmanochakian @devikadasmd @dryukselurun @dan_morgen @ptarantinomd
@DrJNaidoo @NaglaAKarimMD @Lung_Cancers @DrSanjayPopat @tnewsomdavis @Tony_Calles @ns_chd @BalazsHalmosMD @dr_yakupergun @ipreeshagul @FordePatrick @OncNewsCentral @imedverse @acmoorephd @DipeshUpretyMD @Alfdoc2 @g_mountzios @dmavicente @drshieldsmd @DrRiyazShah

[Jasmine Kamboj, MD, FASCO @JasmineKambojMD]

Team Louisiana got the Jeffrey C Ward State award for #Advocacy
#ASCO26
Dr Melanie Sheen 👏

[Dr. Anthony Letai @NCIDirector]

Join me at #ASCO26 for a discussion about reducing delays in oncology clinical trial activation and help patients access promising therapies faster. This will take partnership across NCI, FDA, academia, industry, and the broader research community. https://t.co/tDNt6DEbib

[Kevin Lu @ThinkingCancer]

Honored to have our work on uncommon compound EGFR mutations recognized as a top poster at the @ASCO Resident & Med Student Forum! A massive thank you to my incredible mentors @PatelOncology & @TaliAzen for their guidance and support. #ASCO26 #LCSM @ASCOTECAG

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

Excited to present our poster at #ASCO26 comparing the feasibility of a Geriatric Assessment and Management (GAM) program across public and private oncology services in 🇧🇷

Special thanks to my mentor, @WilliamDale_MD & our incredible collaborators

[Devika Das, MD, MSHQS, FASCO @DevikaDasMD]

@NagashreeSeeth1 I hope the global data is just as good! Such an unmet need. 🤞 I need the study to be more pragmatic and reflective of our real world patients with SCC though 🙏 #lcsm

[Devika Das, MD, MSHQS, FASCO @DevikaDasMD]

Verdict for me: Await the global study results for HARMONY 3 before adoption. Majority of our patients with squamous cell lung cancer are older, have significant cavitation. ( in addition to other co morbidities which make the VEGF AEs harder to tolerate) The benefit in the PDL1 negative squamous tumors is intriguing though. 🤔
Congratulations on this study and this is definitely an un met need! 🙏 #lcsm @asco #ASCO26

[Devika Das, MD, MSHQS, FASCO @DevikaDasMD]

Practice changing!!! What a memorable plenary and journey for RAS 👏👏👏👏 #PDAC @asco #ASCO26
Can’t wait for the #lcsm data now! 👏👏👏😭
Our patients with pancreas cancer ( and all cancer) deserve precision medicine access!